林业发展局停止了Valneva在美国的Chikungunya疫苗销售,因为据报在国外发生了不利事件。 FDA halts Valneva's Chikungunya vaccine sales in U.S. due to adverse events reported abroad.

食品药品管理局已中止Valneva的Chikungunya疫苗(IXCHI), The FDA has suspended Valneva's Chikungunya vaccine, IXCHIQ®, in the US following four new serious adverse events reported outside the country. 这种立即停产的做法阻止了美国所有疫苗的运送和销售。 This immediate suspension halts all shipments and sales of the vaccine in the US. 鉴于疫苗对销售的贡献,Valneva正在调查这些案件并评估财务影响。 Valneva is investigating the cases and assessing the financial impact, given the vaccine's contribution to sales. 该公司仍然致力于让疫苗在全球供应,以预防奇孔古亚爆发。 The company remains committed to the vaccine's global availability for chikungunya outbreak prevention.